Steroidal Compounds Inducing Androgen Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for castration-resistant prostate cancer (CRPC) are not responsive to classical androgen receptor (AR) antagonists, and resistance to therapies like Zytiga and MDV3100 has been reported, necessitating the development of novel compounds that can effectively down-regulate AR expression and activity.
Innovation Solution
Development of novel steroidal compounds that induce AR ablation at low micromolar concentrations, specifically targeting full-length and truncated forms of the androgen receptor, through structural modifications at the C-3, C-16, and C-17 positions, which interact with the AR ligand binding domain to induce degradation and inhibit AR-mediated processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical AR antagonists (hydroxyflutamide or bicalutamide) are used, then AR signaling is inhibited, but CRPC develops resistance and becomes unresponsive to treatment
Solution Approach 1:
The invention changes the mechanism of action parameter from simple antagonism to AR down-regulation through degradation. The novel steroidal compounds induce proteasomal degradation of the androgen receptor, fundamentally altering how AR signaling is inhibited and overcoming resistance mechanisms that developed against classical antagonists.
Solution Approach 2:
The invention introduces an intermediary mechanism involving the proteasome system. The compounds act as mediators that recruit E3 ubiquitin ligases to ubiquitinate the androgen receptor, marking it for degradation by the proteasome, thereby indirectly eliminating AR signaling rather than directly blocking the receptor.
2Reliability
If potent CYP17 inhibitors (abiraterone acetate) are used, then androgen synthesis is inhibited, but resistance to this therapy has already been reported
Solution Approach 1:
Instead of preventing androgen synthesis (upstream approach), the invention inverts the strategy by directly targeting the androgen receptor itself for degradation (downstream approach). This reverses the traditional therapeutic sequence and bypasses resistance mechanisms that developed against CYP17 inhibitors.
3Reliability
If AR down-regulation is achieved, then AR expression is reduced, but novel compounds with appropriate pharmacophore requirements must be developed
Solution Approach 1:
The invention creates composite molecular structures combining steroidal cores with specific heterocyclic moieties (pyridine, pyrimidine, triazine rings). These composite structures integrate multiple functional elements that work synergistically: the steroidal portion provides AR binding affinity while the heterocyclic portions facilitate proteasomal degradation through specific protein-protein interactions.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.